Moolec Science (MLEC) Asset Utilization Ratio (2023 - 2024)
Moolec Science (MLEC) reported Asset Utilization Ratio of 0.25 for Q4 2024, up 118.73% on a YoY basis from 0.11 in Q1 2024, and up 2111.44% sequentially from 0.01 in Q3 2024.
Moolec Science (MLEC) Asset Utilization Ratio (2023 - 2024) Analysis & Trends
Moolec Science (MLEC) has 2 years of Asset Utilization Ratio data on file, last reported at 0.25 in Q4 2024.
- For the quarter ending Q4 2024, Asset Utilization Ratio rose 118.73% year-over-year to 0.25; the trailing twelve-month figure through Dec 2024 stood at 0.25 (up 118.73% YoY), and the FY2024 full-year result was 0.01, down 81.02% from the prior year.
- Asset Utilization Ratio advanced to 0.25 in Q4 2024, from 0.01 in the prior quarter.
- In the past five years, Asset Utilization Ratio ranged from a high of 0.25 in Q4 2024 to a low of 1.98 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 0.69 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 0.47 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 0.37 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Moolec Science | 5.21 Bn | 5.21 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 0.25 |
| Sep 30, 2024 | 0.01 |
| Jun 30, 2024 | 0.01 |
| Mar 31, 2024 | -1.12 |
| Dec 31, 2023 | -1.31 |
| Sep 30, 2023 | -1.24 |
| Jun 30, 2023 | -1.98 |
| Mar 31, 2023 | 0.00 |